Professional Documents
Culture Documents
Marker Report
Marker Report
CLINICAL INFORMATION :
LMP:13/02/2022
ENDOCRINOLOGY
DOUBLE MARKER TEST, SERUM
DOUBLE MARKER
FREE BETA HUMAN CHORIONIC GONADOTROPIN 126.00 ng/mL
METHOD : CHEMILUMINESCENCE,SEQUENTIAL TWO STEP IMMUNOENZYMATIC ASSAY
Page 1 Of 4
CLINICAL INFORMATION :
LMP:13/02/2022
Page 2 Of 4
CLINICAL INFORMATION :
LMP:13/02/2022
Comments
Interpretation(s)
DOUBLE MARKER-
Clinical Information
Multiple marker serum screening has become a standard tool used in obstetrical care to identify pregnancies that may have an increased risk for certain birth defects,
including neural tube defects (NTD), trisomy 21 (Down syndrome), trisomy 13 (Patau syndrome) / trisomy 18 (Edwards syndrome). The screen is performed by measuring
analytes in maternal serum that are produced by the fetus and the placenta. The analyte values along with maternal demographic information such as age, weight,
gestational age, diabetic status, and race are used together in a mathematical model to derive a risk estimate. The laboratory establishes a specific cutoff for each condition,
which classifies each screen as either screen-positive or screen-negative. A screen-positive result indicates that the value obtained exceeds the established cutoff. This test
is a screening test, a positive screen does not provide a diagnosis, but indicates that further evaluation/genetic counseling should be considered.
Incorrect or incomplete information may significantly alter results. Risks are adjusted for donor eggs, frozen embryos, and IVF. Results may be unreliable in twin
pregnancies with a fetal demise. Results are not available for pregnancies with triplets and higher-order multiples.
Reference Values
DOWN SYNDROME
Calculated screen risk of >1:50-1:250 are reported as screen positive.
1:250 risk factor means :Out of 250 women having similar results and history, 1 may have abnormality.
TRISOMY13/ 18
Calculated screen risk of >1:50-1:100 are reported as screen positive.
1:100 risk factor means :Out of 100 women having similar results and history, 1 may have abnormality.
Biological markers evaluated in this test have not been marked as H (High) or L(low) since there is a wide variation in all the biochemical parameters depending upon the
gestational age. “In range” and “out of range” columns are not applicable for the parameters appearing in the Multiple of Median (MoM) and risk calculation.
Note: Obstetric ultra sonogrphy and clinical details furnished in the report are outside NABL scope.
**End Of Report**
Please visit www.srlworld.com for related Test Information for this accession
Dr. Kshama P, MD
Biochemist
Page 3 Of 4
CLINICAL INFORMATION :
LMP:13/02/2022
Page 4 Of 4